The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial

Hanefeld, Markolf; Sachse, G.

doi:10.1046/j.1463-1326.2002.00237.x

Cited by 131 publications

(108 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three were conducted in North America: two in the US alone 11,13 and one in the US and Canada. 12 The other four trials were conducted in Germany, 14 Spain, 15 Thailand 16 and South Africa. 17 The treatment duration was 1 y in four trials, [11][12][13][14] and 6 months in the other three.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

et al. 2005

View full text Add to dashboard Cite

OBJECTIVE:The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes. METHODS: Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled. A subgroup analysis involving patients who achieved a response (defined as a weight loss of Z5% after 12 weeks of treatment) was conducted. The outcomes of the pooled analysis were then used to construct a Markov health economic model covering an 11-y period. The incidences of diabetes-related micro-and macrovascular complications were derived from the United Kingdom Prospective Diabetes Study. The effects of changes in body mass index, and the impact of micro-and macrovascular complications on utilities were derived from published sources. Publicly available cost data were used and are presented here in 2001 Euros. Discounting of 3% was applied. A probabilistic sensitivity analysis was conducted to examine the robustness of results. RESULTS: A total of 1249 patients treated with orlistat and 1230 given placebo were eligible for the intent-to-treat analysis. At the end of the study period, 23% of orlistat patients achieved a weight reduction of Z5%. These patients showed a mean decrease in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2 mmHg. The base-case economic analysis revealed costs per quality-adjusted life year gained of h14 000 in Sweden and h13 600 in Switzerland. CONCLUSION: The data presented here support the utilization and reimbursement of orlistat in overweight and obese diabetic patients who respond to the treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

“…12 The other four trials were conducted in Germany, 14 Spain, 15 Thailand 16 and South Africa. 17 The treatment duration was 1 y in four trials, [11][12][13][14] and 6 months in the other three. In all protocols, patients were randomized to treatment with orlistat 120 mg or placebo t.i.d.…”

Section: Methodsmentioning

confidence: 99%

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

et al. 2005

View full text Add to dashboard Cite

show abstract

“…72 No significant effect on blood pressure compared with dietary/lifestyle-only therapy occurred, except in two studies, one of which involved subjects Long-term efficacy of weight loss methods JD Douketis et al with poorly controlled hypertension. 62,71 Orlistat had inconsistent effects on glycemic control: modest but significantly greater reductions in fasting blood glucose (0.1-1.7 mmol/l) than diet-only therapy in six studies, [60][61][62][63]67,68 but no difference in two studies. 65,66 The greatest improvements in glycemic control occurred in subjects with type 2 diabetes.…”

Section: Jd Douketis Et Almentioning

confidence: 99%

“…No study reported on weight loss and its effects of cardiovascular risk factors in high-risk groups, unless the study was limited to high-risk subjects. 67,68,70,71,73,[75][76][77] …”

Section: Jd Douketis Et Almentioning

confidence: 99%

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

et al. 2005

View full text Add to dashboard Cite

BACKGROUND: Obesity is a common health problem that requires a long-term care approach. We systematically reviewed long-term (Z2 y) studies investigating dietary/lifestyle, pharmacologic, and surgical weight loss methods to assess (1) weight loss efficacy, defined by absolute weight loss and the proportion of subjects with Z5% weight loss, (2) effects of weight loss on cardiovascular risk factors, and (3) applicability of findings from studies to everyday clinical practice. METHODS: The MEDLINE, HealthSTAR, and the Cochrane Controlled Trials databases were searched for studies investigating the long-term efficacy of weight loss methods in overweight and obese adults. Data were extracted for (i) weight loss after 1 y (pharmacologic studies only), 2 y, 3 y, and 4 y, (ii) proportion of subjects with Z5% weight loss at the end of follow-up, and (iii) changes (end-of follow-up minus baseline values) in blood lipids, fasting blood glucose, and systolic and diastolic blood pressure. RESULTS: Dietary/lifestyle therapy provides o5 kg weight loss after 2-4 y, pharmacologic therapy provides 5-10 kg weight loss after 1-2 y, and surgical therapy provides 25-75 kg weight loss after 2-4 y. Weight loss of Z5% baseline weight is not consistently associated with improvements in cardiovascular risk factors and these benefits appear to be intervention specific and occur mainly in people with concomitant cardiovascular risk factors. Weight loss studies have methodologic limitations that restrict the applicability of findings to unselected obese people assessed in everyday clinical practice. These limitations include an inadequate study duration, large proportions of subjects lost to follow-up, a lack of an appropriate usual care group, and a lack of reporting of outcomes in high-risk subgroups. CONCLUSIONS: Dietary/lifestyle and pharmacologic weight loss interventions provide modest weight loss, and may improve markers of cardiovascular risk factors although these benefits occur mainly in patients with cardiovascular risks. Studies investigating weight loss have methodologic limitations that restrict the applicability of findings to obese patients assessed in clinical practice.

show abstract

“…Notably, obesity is often associated with a variety of chronic diseases such as hyperlipidemia, diabetes mellitus, hypertension coronary artery diseases and certain cancers ( Lei et al 2007). Thus, to reduce fat accumulation, the digestion and absorption of fat into the body should be prevented (Hanefeld and Sachse 2002). However, owing to the adverse side effects associated with many antiobesity drugs, more trials have focused on screening natural sources that have been reported to reduce body weight with minimum side effects (Rahul et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet- induced obese rats

et al. 2014

View full text Add to dashboard Cite

Obesity is a chronic metabolic disorder that is associated with numerous diseases including hyperlipidemia, diabetes mellitus, hypertension, atherosclerosis, cardiovascular disease, and cancer. Cinnamic acid is a phytochemical compound having many biological effects and could be considered for the management of obesity. This study is aimed to assess the possible anti-obesity and cardioprotective properties of cinnamic acid (CA) in high fat diet-fed rats (HFD). Male Wistar rats were divided into 4 groups. They received normal diet, HFD diet, HFD supplemented with fluvastatin (2 mg/kg/day) or cinnamic acid (30 mg/kg/day) for 7 weeks. The results showed an increase in body weight of HFD rats bỹ 27 % as compared to control group. Moreover, serum lipase activity underwent a significant rise by 103 % which led to an increase in the levels of total cholesterol (T-Ch), triglycerides (TG), LDL-cholesterol in serum of untreated HFD-fed rats. Furthermore, the concentration of leptin and angiotensinconverting enzyme (ACE) activity exhibited remarkable increases in serum of HFD-fed rats as compared to controls. Whereas, the administration of CA to HFD-fed rats improved the body weight gain and serum lipid profile and reverted back near to normal the activities of lipase and ACE. In addition, the echocardiography evidenced that CA is able to protect the aorta and aortic arch and avoided vasoconstriction by increasing their diameters and improved liver steatosis and kidney indices of toxicity. Overall, these results suggest that cinnamic acid exerts anti-obesity and antihypertensive effects through inhibition of lipid digestive enzymes and ACE.

show abstract

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial

Abstract: Treatment with orlistat plus diet resulted in significant weight loss, improved glycaemic control and cardiovascular risk factor profile in overweight patients with type 2 diabetes.

Cited by 131 publications

References 40 publications

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet- induced obese rats

Contact Info

Product

Resources

About